Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Revolution Medicines, Inc.
Pfizer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Turning Point Therapeutics, Inc.
University Hospitals Coventry and Warwickshire NHS Trust
Revolution Medicines, Inc.
University of Edinburgh
Second Life Therapeutics
Novartis
Revolution Medicines, Inc.
Lund University Hospital
Pfizer
Metanoic Health Ltd.
Purdue University
Hoffmann-La Roche
New Day Diagnostics
Xijing Hospital
University of Sunderland
Thomas Jefferson University
University of Sunderland
National Cancer Center Hospital East
Origin Sciences
Imperial College London
Magentiq Eye LTD
Doncaster And Bassetlaw Hospitals NHS Foundation Trust
University of Aarhus
Leiden University Medical Center
Kyowa Kirin Co., Ltd.
University Hospital, Antwerp
Shandong Provincial Hospital
Catalysis SL
Vastra Gotaland Region
Sumitomo Pharma America, Inc.
Fujian Cancer Hospital
RenJi Hospital
Hoffmann-La Roche
Fudan University
University Hospital Plymouth NHS Trust
Kilis 7 Aralik University
RenJi Hospital
RenJi Hospital
Sociedad Española de Medicina Nuclear e Imagen Molecular
Parc Taulí Hospital Universitari
St George's, University of London
RenJi Hospital
RenJi Hospital
Zhejiang University
Magentiq Eye LTD
State Scientific Centre of Coloproctology, Russian Federation
Asociación Española de Gastroenterología